Prolactinoma When Cabergoline Dose Escalation Has Not Achieved Prolactin Normalisation or Adequate Tumour Reduction
This protocol addresses prolactinoma that has not responded adequately to maximally escalated cabergoline therapy — a recognised threshold that triggers consideration of the next step in management.
Prior Treatment — Insufficient Response
The previous treatment line involved escalation of cabergoline to the maximally tolerated dose. This strategy did not achieve the required goals: normalisation of prolactin levels and at least 50% reduction in tumour size. Failure to meet these targets is the indication for escalation to this protocol.
Approach at this stage: A surgical intervention via the transsphenoidal route is considered, forming part of a multimodal strategy. How this is combined with other therapies, and under what circumstances, is set out in the full protocol.
References
DOI: 10.1210/clinem/dgad174
- Resistance to cabergoline represents the first clear indication for surgery in prolactinomas (146), together with pituitary apoplexy, intolerance to DA, persistent chiasmal compression despite optimal medical therapy, cerebrospinal fluid leak while on DA, and psychiatric conditions in macroadenomas.
- Nevertheless, some patients may require a multimodal therapeutic approach, including the association of medical therapy and surgery, ultimately combined with radiotherapy, particularly in presence of aggressive tumors, as in clinical case 3.
View source ↗